New therapies for fungal pneumonia
Johan Maertens1, Wouter Meersseman, Pascal Van Bleyenbergh
1Department of Hematology, Acute Leukemia and Stem Cell Transplantation Unit, University Hospitals Leuven, Campus Gasthuisberg, Herestraat 49, Leuven, Belgium. johan.maertens@uz.kuleuven.ac.be
Purpose Of Review:
This review summarizes recent developments in the diagnosis and treatment of fungal pneumonia, with an emphasis on invasive pulmonary aspergillosis.
Recent Findings:
Improvements in nonculture-based fungal diagnostics, early implementation of pulmonary high resolution, or spiral computed tomography scanning and a recent expansion of the antifungal armamentarium have greatly improved the outcome of immunocompromised patients with invasive aspergillosis. However, the field is changing: new pathogens (such as Zygomycetes) are emerging, and novel risk groups (ICU patients in particular) are being identified.
Summary:
Galactomannan antigen detection is a valuable tool for evaluating patients at risk for invasive aspergillosis (as a screening assay on serum samples from neutropenic patients or as a confirmatory assay on bronchoalveolar lavage fluid samples, in general), but should be used in conjunction with modern imaging techniques. beta-D-Glucan and PCR assays are still investigational. Voriconazole is the drug of choice for invasive aspergillosis, whereas liposomal amphotericin B at 3 mg/kg per day is the preferred alternative in case of contraindication, drug-related side-effects, or intolerance. Whenever possible, optimal antifungal therapy should be complemented by surgical debridement of necrotic tissue. The added value of combination therapy is still unproven. Therapeutic drug monitoring of mold-active azoles should be implemented in order to minimize toxicity and maximize efficacy. Lipid-based formulations of amphotericin B, and to a lesser extent voriconazole, are the drugs of choice for non-Aspergillus related fungal pneumonia. Although active in prophylaxis, the efficacy of posaconazole in confirmed infections remains controversial.
Insights
Recent advances in diagnosing and treating invasive aspergillosis improve outcomes for immunocompromised patients. New diagnostics and antifungal drugs are key, but emerging pathogens and patient groups require ongoing research.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pulmonology
Background:
- Fungal pneumonia, particularly invasive pulmonary aspergillosis, poses a significant threat to immunocompromised individuals.
- The landscape of fungal pathogens and at-risk patient populations is evolving, necessitating updated diagnostic and therapeutic strategies.
Purpose of the Study:
- To review recent advancements in the diagnosis and treatment of fungal pneumonia.
- To focus on invasive pulmonary aspergillosis in immunocompromised patients.
Main Methods:
- Review of current literature on fungal pneumonia diagnostics and therapeutics.
- Emphasis on nonculture-based diagnostic methods, advanced imaging, and antifungal agents.
- Analysis of emerging pathogens and novel risk groups.
Main Results:
- Nonculture-based diagnostics (e.g., galactomannan antigen detection) and advanced imaging (CT scans) improve invasive aspergillosis outcomes.
- Voriconazole is the primary treatment for invasive aspergillosis; liposomal amphotericin B is a key alternative.
- Emerging pathogens like Zygomycetes and increased incidence in ICU patients are noted.
Conclusions:
- Galactomannan antigen detection is valuable but requires integration with imaging.
- Voriconazole is the preferred agent for invasive aspergillosis, with lipid formulations of amphotericin B for other fungal pneumonias.
- Therapeutic drug monitoring and surgical debridement are important adjuncts; combination therapy efficacy is unproven.
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:27Cryptococcal Meningitis
01:15Antifungal Agents
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:29Pneumonia II: Pathophysiology
01:14Atypical Pneumonia